Soleno Therapeutics

105 articles about Soleno Therapeutics

• Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 08, 2024

  3/8/2024

  Soleno Therapeutics, Inc. announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to five new employees.

• Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

  3/6/2024

  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2023.

• Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

  2/22/2024

  Soleno Therapeutics, Inc. today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024, at 1:30 PM Eastern Time.

• Soleno Therapeutics to Present at Upcoming February Investor Conferences

  2/1/2024

  Soleno Therapeutics, Inc. today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the following upcoming investor conferences.

• Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 29, 2024

  1/29/2024

  Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to five new employees.

• Soleno Therapeutics Strengthens Leadership Team with Key Appointments

  1/24/2024

  Soleno Therapeutics, Inc. today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources.

• Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  1/5/2024

  Soleno Therapeutics, Inc.  today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to three new employees.

• Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 10, 2023

  11/10/2023

  Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to two new employees.

• Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

  11/7/2023

  Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, provided a corporate update and reported financial results for the third quarter ended September 30, 2023.

• Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome

  11/6/2023

  Soleno Therapeutics, Inc. today announced publication of one-year results from the Phase 3 DESTINY PWS study and the open-label extension period of Study C602 evaluating investigational, once-daily DCCR (Diazoxide Choline) Extended-Release tablets for patients with Prader-Willi syndrome (PWS).

• Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

  10/4/2023

  Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced an oral presentation at the Foundation for Prader-Willi Research 2023 Research Symposium, being held October 5-6, 2023, in Denver, Colorado.

• Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

  10/4/2023

  Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced an oral presentation at the Foundation for Prader-Willi Research 2023 Research Symposium, being held October 5-6, 2023, in Denver, Colorado.

• Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  10/2/2023

  Soleno Therapeutics, Inc. announced the closing of the underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $20.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares.

• Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

  9/28/2023

  Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $20.00 per share.

• Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

  9/27/2023

  Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced that it intends to offer and sell shares of its common stock and/or pre-funded warrants in an underwritten public offering.

• Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

  9/26/2023

  Soleno Therapeutics, Inc. today announced positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS).

• Soleno Therapeutics to Present at the Cantor Global Healthcare Conference

  9/25/2023

  Soleno Therapeutics, Inc. today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 8:10 AM Eastern Time.

• Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

  8/16/2023

  Soleno Therapeutics, Inc. today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023.

• Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

  8/8/2023

  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.

• Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

  5/9/2023

  Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, provided a corporate update and reported financial results for the first quarter ended March 31, 2023.